AstraZeneca’s antibody drug prevents Covid-19 in high-risk groups: Study, Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com

Results from Astra’s study found no one in the trial who received the cocktail contracted severe Covid-19 or died in relation to the disease, the company said in a statement on Friday. The trial of 5,197 participants, which started in November, was looking at whether the drug could prevent infection in at-risk groups and took place in the US, UK, Belgium, France and Spain., Results from Astra’s study found no one in the trial who received the cocktail contracted severe Covid-19 or died in relation to the disease, the company said in a statement on Friday. The trial of 5,197 participants, which started in November, was looking at whether the drug could prevent infection in at-risk groups and took place in the US, UK, Belgium, France and Spain., , Read More